A comparison between restricted maximum likelihood method and method of moments for evaluation of individual bioequivalence
碩士 === 國立成功大學 === 統計學系 === 88 === Abstract The aim of bioequivalence trials is to demonstrate two formulations (test and reference) of a drug have similar bioavailability. In 1997, the U.S. Food and Drug Administration (FDA) proposed an aggregate criterion, called CR3, to assess individua...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2000
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/83299548167365923623 |